Explore the SOURCE 3 Registry: Real-World Evidence With the Edwards SAPIEN 3 Transcatheter Heart Valve

Sponsored by Edwards Lifesciences

At EuroPCR 2017, new one-year data from a post-approval study of the Edwards SAPIEN 3 valve demonstrated positive patient outcomes, including high survival rates, low rates of stroke, and low rates of paravalvular leak.

The majority of patients in the SOURCE 3 Registry were treated via transfemoral access, and more than half were treated under conscious sedation. SOURCE 3 patients were enrolled at 80 centres across 10 countries between July 2014 and October 2015, and will continue to be followed for five years post-TAVI.

SOURCE 3 post-approval registry—One-year outcomes in 1,946 TAVI patients with a 3rd generation balloon transcatheter heart valve

 
Speaker: O. Wendler

  • At 1 year, patients treated via the transfemoral access route had a high survival rate (88.2 percent) and a low disabling stroke rate (1.1 percent).
  • Patients experienced a low rate (2.7 percent) of moderate paravalvular leak and no severe paravalvular leak.
     

Watch the presentation

Characteristics and outcomes of patients ≤75 years old undergoing TAVI—Insights from the SOURCE 3 registry

 
Speaker: D. Frank

Read the presentation

Characteristics and outcomes of patients ≤75 years old undergoing TAVI—Insights from the SOURCE 3 registry

Surgical risk and outcomes of patients undergoing TAVI with the Edwards SAPIEN 3 bioprosthesis: A subanalysis of the SOURCE 3 registry

 
Speaker: G. Tarantini

Read the presentation

Surgical risk and outcomes of patients undergoing TAVI with the Edwards SAPIEN 3 bioprosthesis: A subanalysis of the SOURCE 3 registry

 

TAVI with the Edwards SAPIEN 3TM Valve

Changing the World of Aortic Stenosis Therapy

 
Visit SAPIEN3.com  to see how SAPIEN 3 TAVI is transforming treatment today.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Material for distribution only in countries with applicable health authority product registrations. Material not intended for distribution in USA or Japan. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, PARTNER, PARTNER II, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation.

© 2017 Edwards Lifesciences Corporation. All rights reserved. E7165/07-17/THV

Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com

Page published on July 2017

Sponsor

With an unrestricted educational grant from Edwards Lifesciences

Disclaimer

This case report does not reflect the opinion of PCR or PCRonline, nor does it engage their responsibility.